According to a recent LinkedIn post from SK bioscience, the company has secured KRW 4 billion (about USD 3.0 million) in funding from the RIGHT Foundation to advance its RSV preventive antibody candidate RSM01 into a Phase 1b clinical trial. The post notes that RSM01, licensed from the Gates Medical Research Institute, is designed as a single-dose protection for infants across the RSV season and has shown promising early data.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights ambitions for both global commercialization and improved access in underserved regions, framing the project as a step toward global health equity. For investors, the external, grant-like funding may help de‑risk early clinical development costs, support SK bioscience’s positioning in the pediatric infectious disease market, and potentially enhance its reputation with global health partners if clinical progress and access objectives materialize.